Summary:
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
Criteria:Subject has at least a 6 month history of migraine (with or without aura) and including the following
- Male and female subjects ≥ 6 to <18 years; subjects must be less than 18 at the time of signing assent / consent
- Subjects must have a weight of ≥40 kg (child cohort requirement ≥15 kg) at the Screening Visit
- Subject to addtional inclusion/exclusion criteria